$0.11
(Market cap
$72 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-4 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-4
-
Face value
--
-
Shares outstanding
3,125,840
6 Years Aggregate
CFO
$-133.04 Mln
EBITDA
$-150.30 Mln
Net Profit
$-148.27 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Landos Biopharma (LABP)
| 526.0 | 4.3 | 296.4 | 655.9 | -42.5 | -- | -- |
|
BSE Sensex*
| -11.9 | -3.9 | -11.5 | -6.2 | 6.4 | 8.7 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Landos Biopharma (LABP)
| -26.8 | -89.6 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Landos Biopharma (LABP)
|
22.9 | 71.7 | 0.0 | -24.8 | -- | -81.5 | -- | 2.1 |
| 0.1 | 3.6 | 0.3 | -95.1 | -21,828.5 | -265.1 | -- | 0.3 | |
| 25.6 | 2,212.9 | 174.9 | -190.4 | -118.4 | -54.6 | -- | 7.0 | |
| 2.1 | 6.0 | 0.1 | -6.2 | -15,087.2 | -15.2 | -- | 1.9 |
Shareholding Pattern
View DetailsAbout Landos Biopharma (LABP)
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1),... a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia. As of May 23, 2024, Landos Biopharma, Inc. operates as a subsidiary of AbbVie Inc. Read more
-
President, CEO & Director
Mr. Gregory Oakes
-
President, CEO & Director
Mr. Gregory Oakes
-
Headquarters
Blacksburg, VA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Landos Biopharma (LABP)
What is the current share price of Landos Biopharma Inc (LABP) Today?
The share price of Landos Biopharma Inc (LABP) is $22.91 (NASDAQ) as of 23-May-2024 16:37 EDT. Landos Biopharma Inc (LABP) has given a return of -42.51% in the last 3 years.
What is the current PB & PE ratio of Landos Biopharma Inc (LABP)?
Since, TTM earnings of Landos Biopharma Inc (LABP) is negative, P/E ratio is not available.
The P/B ratio of Landos Biopharma Inc (LABP) is 2.11 times as on 11-Jun-2024, a 51 discount to its peers’ median range of 4.29 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-1.04
|
0.71
|
|
2022
|
-0.05
|
0.05
|
|
2021
|
-0.51
|
0.25
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
What is the 52 Week High and Low of Landos Biopharma Inc (LABP)?
The 52-week high and low of Landos Biopharma Inc (LABP) are Rs -- and Rs -- as of 12-May-2026.
What is the market cap of Landos Biopharma Inc (LABP)?
Landos Biopharma Inc (LABP) has a market capitalisation of $ 72 Mln as on 11-Jun-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in Landos Biopharma Inc (LABP)?
Before investing in Landos Biopharma Inc (LABP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.